Page last updated: 2024-12-04

bis(4-nitrophenyl)phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(4-nitrophenyl)phosphate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID255
CHEMBL ID1231178
CHEBI ID3122
SCHEMBL ID223704
MeSH IDM0043693

Synonyms (55)

Synonym
AC-19748
bis(4-nitrophenyl)phosphoric acid
phosphoric acid bis(p-nitrophenyl ester)
phosphoric acid bis(p-nitrophenyl) ester
mls002693253 ,
nsc-59824
p-nitrophenyl monohydrogen phosphate
phosphoric acid, bis(4-nitrophenyl) ester
phosphoric acid, bis(p-nitrophenyl) ester
nsc59824
einecs 211-434-7
nsc 59824
phenol, p-nitro-, hydrogen phosphate
brn 2064857
bis(4-nitrophenyl) hydrogen phosphate
bis(p-nitrophenyl)phosphate
phosphorsaeure-bis-(p-nitro-phenylester) [german]
bis(p-nitrophenyl) phosphate
645-15-8
bnpp
bis(4-nitrophenyl)phosphate
bis-4-nitrophenyl phosphate
di-p-nitrophenyl phosphate
C03779
bis(4-nitrophenyl) phosphate
bis(4-nitrophenyl) phosphate, 99%
NCIOPEN2_007976
phosphoric acid bis(4-nitrophenyl) ester
B1098 ,
smr001559212
bdbm50130915
chebi:3122 ,
chembl1231178 ,
b4n ,
DB07418
HMS3085F04
phosphorsaeure-bis-(p-nitro-phenylester)
unii-1mf77lei63
1mf77lei63 ,
4-06-00-01330 (beilstein handbook reference)
FT-0632740
AKOS015906713
SCHEMBL223704
W-104830
bis[4-nitrophenyl]phosphate
bis(4-nitrophenyl) hydrogen phosphate #
mfcd00007318
DTXSID20870742
bis(p-nitrophenyl) hydrogen phosphate
Q27096640
AS-17229
CS-W013921
phosphoric acid bis-(4-nitro-phenyl)ester
F11268
SY057312

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In the present study, the putative toxic metabolites of DBE, the monomethyl esters and the dicarboxylic acids, were evaluated in the nasal explant system at concentrations ranging from 10 to 50 mM."( Cytotoxicity of dibasic esters (DBE) metabolites in rat nasal explants.
Bogdanffy, MS; Trela, BA, 1991
)
0.28
" Toxic doses of acetylisoniazid and acetylhydrazine, radiolabeled in the acetyl group, were found to bind covalently to liver protein in vivo."( Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.
Mitchell, JR; Nelson, SD; Snodgrass, WR; Timbrell, JA, 1980
)
0.26
" Resin monomers are the main toxic components in DBA, and the ester group is crucial for monomer toxicity."( Carboxylesterase expression in human dental pulp cells: role in regulation of BisGMA-induced prostanoid production and cytotoxicity.
Chan, CP; Chang, MC; Chuang, FH; Jeng, JH; Jeng, PY; Lee, JJ; Lin, HJ; Lin, LD; Tseng, WY; Wang, TM, 2012
)
0.38
"The toxic effect of urethane dimethacrylate (UDMA), a major dental resin monomer, on human dental pulp is not fully clear."( Urethane dimethacrylate induces cytotoxicity and regulates cyclooxygenase-2, hemeoxygenase and carboxylesterase expression in human dental pulp cells.
Chan, CP; Chang, HH; Chang, MC; Huang, GF; Jeng, JH; Lee, YL; Tseng, SK; Wang, HH; Wang, YL; Yeung, SY, 2014
)
0.4

Pharmacokinetics

ExcerptReferenceRelevance
"A pharmacokinetic model for the accumulation of di-2-ethylhexyl phthalate (DEHP) by sheepshead minnow predicted a significant increase in the bioconcentration factor (BCF) of DEHP if its metabolism were inhibited."( Metabolic inhibition and di-2-ethylhexyl phthalate pharmacokinetics in fish.
Hayton, WL; Karara, AH,
)
0.13
" In the other two routes of administration via the tail vein and hepatic portal vein, diammonium glycyrrhizinate (15 mg kg(-1)) did not affect any of the pharmacokinetic parameters of aconitine (0."( Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism.
Chen, L; Chen, YX; Davey, AK; Liu, XQ; Wang, JP; Yang, J, 2009
)
0.35
" The validated method was successfully applied to a pharmacokinetic study in rats after the intratracheal administration of zeylenone in free drug or polymeric micellar solutions."( Stabilization of zeylenone in rat plasma by the presence of esterase inhibitors and its LC-MS/MS assay for pharmacokinetic study.
Chang, Q; Han, R; Hu, X; Liao, YH; Liu, CY; Quan, LH; Wei, XL, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" After oral administration of diammonium glycyrrhizinate (50 mg kg(-1)), the peak plasma concentration (C(max)), area under the plasma concentration-time curve from zero to time tau (AUC(0-tau)), and absolute bioavailability of aconitine (0."( Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism.
Chen, L; Chen, YX; Davey, AK; Liu, XQ; Wang, JP; Yang, J, 2009
)
0.35
" A liquid chromatography-tandem mass spectrometry method was applied to determine the oral bioavailability of ethyl piperate."( Contribution of carboxylesterase in hamster to the intestinal first-pass loss and low bioavailability of ethyl piperate, an effective lipid-lowering drug candidate.
Bao, N; Borjihan, G; Hu, M; Jia, J; Li, S; Lu, Y; Ma, Y; Wang, Y; Yang, D; Yu, C, 2011
)
0.37
"Human carboxylesterase 2 (hCE2), one of the major carboxylesterases in the human intestine and various tumour tissues, plays important roles in the oral bioavailability and treatment outcomes of ester- or amide-containing drugs or prodrugs, such as anticancer agents CPT-11 (irinotecan) and LY2334737 (gemcitabine)."( Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2.
Ge, GB; Hao, DC; Hou, J; Jin, Q; Li, YG; Wang, P; Yang, L; Zhou, K; Zou, LW, 2016
)
0.43
" It plays crucial roles in the bioavailability of oral ester prodrugs and the therapeutic effect of some anticancer drugs such as irinotecan (CPT11) and capecitabine."( Discovery of pyrazolones as novel carboxylesterase 2 inhibitors that potently inhibit the adipogenesis in cells.
Bao, X; Guan, XQ; Jin, Q; Li, SY; Ma, HY; Qian, XK; Song, PF; Wang, DD; Zhang, J; Zhao, YS; Zou, LW, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Coupled with exposure to metabolically formed acetaldehyde at high administered concentrations, nonlinear dose-response curves for epithelial tumors are produced."( Vinyl acetate-induced intracellular acidification: implications for risk assessment.
Bogdanffy, MS, 2002
)
0.31
" Additionally, CES1 genetic variants have the potential to serve as a biomarker to predict clopidogrel response and individualize clopidogrel dosing regimens in clinical practice."( Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
Angiolillo, DJ; Brinda, BJ; Gawronski, BE; Markowitz, JS; Wang, X; Zhu, HJ, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aryl phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
importin subunit beta-1 isoform 1Homo sapiens (human)Potency15.47285.804836.130665.1308AID540253; AID540263
snurportin-1Homo sapiens (human)Potency15.47285.804836.130665.1308AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency18.35645.804816.996225.9290AID540253
Guanine nucleotide-binding protein GHomo sapiens (human)Potency7.07951.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cocaine esteraseHomo sapiens (human)IC50 (µMol)5.21500.00582.43306.8000AID1255832; AID1763792
Liver carboxylesterase 1Homo sapiens (human)IC50 (µMol)0.20000.00400.25510.6000AID1647988
Liver carboxylesteraseSus scrofa (pig)IC50 (µMol)1.80000.00240.93591.8000AID1399484; AID1465114; AID1486125; AID1610479; AID1762401
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
prostaglandin metabolic processCocaine esteraseHomo sapiens (human)
xenobiotic metabolic processCocaine esteraseHomo sapiens (human)
catabolic processCocaine esteraseHomo sapiens (human)
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
methylumbelliferyl-acetate deacetylase activityCocaine esteraseHomo sapiens (human)
carboxylesterase activityCocaine esteraseHomo sapiens (human)
carboxylic ester hydrolase activityCocaine esteraseHomo sapiens (human)
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
endoplasmic reticulumCocaine esteraseHomo sapiens (human)
endoplasmic reticulum lumenCocaine esteraseHomo sapiens (human)
intracellular membrane-bounded organelleCocaine esteraseHomo sapiens (human)
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1465117Antioxidant activity assessed as ABTS radical cation scavenging activity by measuring trolox equivalents at 20 uM after 1 hr by UV/Vis spectrophotometric method-based ABTS radical cation decolorization assay2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
AID1486125Inhibition of porcine liver carboxylesterase using 4-nitrophenol acetate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
Synthesis, molecular docking, and biological activity of polyfluoroalkyl dihydroazolo[5,1-c][1,2,4]triazines as selective carboxylesterase inhibitors.
AID1352299Inhibition of CE2 in human liver microsomes using fluorescein diacetate as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by luminescence assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Bysspectin A, an unusual octaketide dimer and the precursor derivatives from the endophytic fungus Byssochlamys spectabilis IMM0002 and their biological activities.
AID1610481Inhibition of human erythrocyte AChE at 20 uM using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition by Ellman's method relative to control2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis of 2-arylhydrazinylidene-3-oxo-4,4,4-trifluorobutanoic acids as new selective carboxylesterase inhibitors and radical scavengers.
AID1465114Inhibition of pig liver carboxylesterase using 4-nitrophenol acetate as substrate by spectrophotometric analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
AID1399481Inhibition of human erythrocyte AChE at 20 uM using acetylthiocholine iodide as substrate incubated for 10 mins followed by substrate addition by Ellman's method relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis, molecular docking, and biological activity of 2-vinyl chromones: Toward selective butyrylcholinesterase inhibitors for potential Alzheimer's disease therapeutics.
AID1285101Selectivity ratio of IC50 for CE1 in human liver microsomes to IC50 for CE2 in human liver microsomes2016European journal of medicinal chemistry, Apr-13, Volume: 112Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2.
AID1610483Antioxidant activity assessed as decrease in ABTS radical cation scavenging activity every 1 min for 6 mins by UV-Vis spectrophotometric analysis2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis of 2-arylhydrazinylidene-3-oxo-4,4,4-trifluorobutanoic acids as new selective carboxylesterase inhibitors and radical scavengers.
AID1465120Inhibition of equine serum BChE at 20 uM using butyrylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition by Ellman's method2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
AID1762408Antioxidant activity assessed as decrease in ABTS radical cation scavenging activity incubated for 24 hrs by UV-Vis spectrophotometric analysis2021European journal of medicinal chemistry, Jun-05, Volume: 218Novel potent bifunctional carboxylesterase inhibitors based on a polyfluoroalkyl-2-imino-1,3-dione scaffold.
AID1486126Inhibition of human erythrocyte acetylcholinesterase at 20 uM using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition by Ellman's method relative to control2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
Synthesis, molecular docking, and biological activity of polyfluoroalkyl dihydroazolo[5,1-c][1,2,4]triazines as selective carboxylesterase inhibitors.
AID1610479Inhibition of porcine liver carboxylesterase using 4-NPA as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis of 2-arylhydrazinylidene-3-oxo-4,4,4-trifluorobutanoic acids as new selective carboxylesterase inhibitors and radical scavengers.
AID1285100Inhibition of CE1 in human liver microsomes using 2-(2-Benzoyl-3-methoxyphenyl) benzothiazole as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by LC-UV analysis2016European journal of medicinal chemistry, Apr-13, Volume: 112Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2.
AID1399484Inhibition of porcine liver carboxylesterase using 4-nitrophenol acetate as substrate incubated for 10 mins followed by substrate addition by spectrophotometric method2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis, molecular docking, and biological activity of 2-vinyl chromones: Toward selective butyrylcholinesterase inhibitors for potential Alzheimer's disease therapeutics.
AID1762404Inhibition of human erythrocyte AChE at 20 uM using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition by Ellman's method relative to control2021European journal of medicinal chemistry, Jun-05, Volume: 218Novel potent bifunctional carboxylesterase inhibitors based on a polyfluoroalkyl-2-imino-1,3-dione scaffold.
AID1647988Inhibition of human CE1 using D-luciferin methyl ester as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by luminescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
Yanhusanines A-F, Isoquinoline-Derived Alkaloid Enantiomers from
AID1399483Inhibition of equine serum BChE at 20 uM using butylthiocholine iodide as substrate incubated for 10 mins followed by substrate addition by Ellman's method relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis, molecular docking, and biological activity of 2-vinyl chromones: Toward selective butyrylcholinesterase inhibitors for potential Alzheimer's disease therapeutics.
AID1486127Inhibition of equine serum butyrylcholinesterase at 20 uM using butyrylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition by Ellman's method relative to control2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
Synthesis, molecular docking, and biological activity of polyfluoroalkyl dihydroazolo[5,1-c][1,2,4]triazines as selective carboxylesterase inhibitors.
AID1399488Antioxidant activity assessed as ABTS radical cation scavenging activity by measuring trolox equivalent antioxidant capacity at 20 uM after 1 hr by UV/Vis spectrophotometric analysis2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis, molecular docking, and biological activity of 2-vinyl chromones: Toward selective butyrylcholinesterase inhibitors for potential Alzheimer's disease therapeutics.
AID1255832Inhibition of human carboxylesterase 2 using 4-benzoyl-N-butyl-1,8-naphthalimide as substrate by fluorescence assay2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Protostane Triterpenoids from the Rhizome of Alisma orientale Exhibit Inhibitory Effects on Human Carboxylesterase 2.
AID1285099Inhibition of CE2 in human liver microsomes using fluorescein diacetate as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by LC-UV analysis2016European journal of medicinal chemistry, Apr-13, Volume: 112Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2.
AID1465119Inhibition of human erythrocyte AChE at 20 uM using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition Ellman's method2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
AID1762401Inhibition of porcine liver carboxylesterase using 4-NPA as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis2021European journal of medicinal chemistry, Jun-05, Volume: 218Novel potent bifunctional carboxylesterase inhibitors based on a polyfluoroalkyl-2-imino-1,3-dione scaffold.
AID1647989Inhibition of human CE2 using fluorescein diacetate as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by luminescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
Yanhusanines A-F, Isoquinoline-Derived Alkaloid Enantiomers from
AID1465118Antioxidant activity assessed as ABTS radical cation scavenging activity after 1 hr by UV/Vis spectrophotometric method-based ABTS radical cation decolorization assay2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
AID1352298Inhibition of CE1 in human liver microsomes using D-Luciferin methyl ester as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by luminescence assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Bysspectin A, an unusual octaketide dimer and the precursor derivatives from the endophytic fungus Byssochlamys spectabilis IMM0002 and their biological activities.
AID1459737Inhibition of DLODP in human HepG2 microsomal membrane assessed as reduction in [3H]OSP production using Glc3-0[3H]Man9-5GlcNAc2-PP-dolichol as substrate at pH 5.5 measured after 20 to 60 mins by scintillation counting2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis and biological evaluation of chemical tools for the study of Dolichol Linked Oligosaccharide Diphosphatase (DLODP).
AID1763792Inhibition of CES2 in human liver microsomes assessed as reduction in substrate hydrolysis using fluorescein diacetate as substrate preincubated for 3 mins followed by substrate addition and measured after 20 mins by fluorescence analysis2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of pyrazolones as novel carboxylesterase 2 inhibitors that potently inhibit the adipogenesis in cells.
AID1610487Potency index, ratio of trolox IC50 to test compound IC50 for antioxidant activity assessed as decrease in ABTS radical cation scavenging activity2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis of 2-arylhydrazinylidene-3-oxo-4,4,4-trifluorobutanoic acids as new selective carboxylesterase inhibitors and radical scavengers.
AID1610482Inhibition of equine serum BuChE at 20 uM using butyrylcholine iodide as substrate preincubated for 10 mins followed by substrate addition by Ellman's method relative to control2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis of 2-arylhydrazinylidene-3-oxo-4,4,4-trifluorobutanoic acids as new selective carboxylesterase inhibitors and radical scavengers.
AID1762407Antioxidant activity assessed as trolox equivalent of ABTS radical cation scavenging activity incubated for 24 hrs by UV-Vis spectrophotometric analysis2021European journal of medicinal chemistry, Jun-05, Volume: 218Novel potent bifunctional carboxylesterase inhibitors based on a polyfluoroalkyl-2-imino-1,3-dione scaffold.
AID1762406Inhibition of equine serum BuChE at 20 uM using butyrylcholine iodide as substrate preincubated for 10 mins followed by substrate addition by Ellman's method relative to control2021European journal of medicinal chemistry, Jun-05, Volume: 218Novel potent bifunctional carboxylesterase inhibitors based on a polyfluoroalkyl-2-imino-1,3-dione scaffold.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (142)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (20.42)18.7374
1990's24 (16.90)18.2507
2000's38 (26.76)29.6817
2010's43 (30.28)24.3611
2020's8 (5.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.29 (24.57)
Research Supply Index5.00 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index27.81 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.68%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other146 (99.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]